¹è½ÃÇö ¸íÀÇ

°£¼¼Æ÷¾Ï°ú °£°æÈ­ÀÇ °£À̽Ä-°£Áٱ⼼Æ÷ Ä¡·á ±ÇÀ§ÀÚ·Î ¸ö°ú ¸¶À½À» ÇÔ²² Ä¡·áÇÏ´Â ÀÇ»ç

¹è½ÃÇö ¸íÀÇ

  • ¼Ò ¼Ó
    °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼ÒÈ­±â³»°ú
  • Àü¹®ºÐ¾ß
    °£¼¼Æ÷¾Ï, °£°æÈ­, °£À̽Ä, Áٱ⼼Æ÷ Ä¡·á

°¡Å縯´ëÇб³ Àǰú´ëÇÐÀ» Á¹¾÷Çϰí ÇöÀç °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼ÒÈ­±â³»°ú ±³¼ö·Î ÀçÁ÷ ÁßÀÌ¸ç º´¿øÀåÀ» ¸Ã°í ÀÖ´Ù.
°£¼¼Æ÷¾Ï°ú °£°æÈ­ÀÇ °£À̽Ä/°£Áٱ⼼Æ÷ Ä¡·á ºÐ¾ß ±ÇÀ§ÀÚ·Î ²ÅÈ÷´Â ¹è½ÃÇö ±³¼ö´Â, Ä¡·á°¡ ¾î·Á¿î ÁøÇ༺ °£¼¼Æ÷¾Ï ȯÀÚ¿¡°Ô ´ÙÇÐÁ¦ ÇùÁøÀ» ÅëÇØ ÃÖÀûÈ­µÈ Ä¡·á·Î È¿°ú¸¦ ±Ø´ëÈ­½Ã۰í ÀÖ´Ù. ƯÈ÷, À̽ÄÀÌ ÇÊ¿äÇÒ Á¤µµ·Î ½É°¢ÇÑ °£°æÈ­ ȯÀÚ¿¡°Ô °£Áٱ⼼Æ÷ Àӻ󿬱¸¸¦ ¼±µµÀûÀ¸·Î ÁÖµµÇϰí ÀÖ´Ù.
±âÃÊ ¿¬±¸·Î´Â °£¼¶À¯È­¸¦ Á¶ÀýÇÏ´Â ¸é¿ª°ü·Ã Ä¡·á ¿¬±¸·Î °£Áúȯ Ä¡·á È¿´É ¿¹Ãø ¹ÙÀÌ¿À¸¶Ä¿ °³¹ß°ú °£¼¶À¯È­ Ä¡·áÁ¦ °³¹ß, miRNAÀ»±â¹ÝÀ¸·Î ÇÑ °£Áٱ⼼Æ÷ ¿¬±¸¸¦ ±¹Ã¥°úÁ¦·Î ¼öÇàÇϰí ÀÖ´Ù. ´ëÇѰ£ÇÐȸ, ´ëÇѰ£¾ÏÇÐȸ, ´ëÇѼÒÈ­±âÇÐȸ µîÀ» ÅëÇØ Ȱ¹ßÇÑ Çмú Ȱµ¿À» ÆîÄ¡°í ÀÖÀ¸¸ç, ´ëÇѰ£ÇÐȸ 15´ë ÀÌ»çÀå, ¾Æ½Ã¾ÆÅÂÆò¾ç°£ÇÐȸ2022 »ç¹«ÃÑÀå°ú ¾Æ½Ã¾ÆÅÂÆò¾ç°£ÇÐȸ 2023STC Á¶Á÷À§¿øÀåÀ» ¿ªÀÓÇß´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • 1984~1990 °¡Å縯´ëÇб³ ÀÇÇÐ Çлç
  • 1992~1994 °¡Å縯´ëÇб³ ³»°úÇÐ ¼®»ç
  • 1994~2000 °¡Å縯´ëÇб³ ³»°úÇÐ ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • 2023~ÇöÀç ÀºÆò¼º¸ðº´¿ø Á¦ 4´ë º´¿øÀå
  • 2002.8.1 ~2004.2. 14 ¹Ì±¹ University of Florida, ¿¬±¸ ±³¼ö, °£Áٱ⼼Æ÷

¼ö»ó³»¿ª

Awards List
  • 2023³â 11¿ù 30ÀÏ ±¹¹«ÃѸ® ǥâ: CÇü °£¿° °¨¿°¿¹¹æ »ç¾÷
  • 2018³â ´ëÇѰ£ÇÐȸ-GSK Çмú³í¹®»ó ¼ö»ó
  • 2012³â ´ëÇѰ£ÇÐȸ ÃÖ¿ì¼ö ³í¹®»ó ¼ö»ó
  • 2010³â 7th APASL-STC ¿ì¼ö ³í¹®»ó ¼ö»ó
  • 2010³â ´ëÇѳ»°úÇÐȸ ¿ì¼ö ³í¹®»ó ¼ö»ó

ÇÐȸȰµ¿

Academic activities
  • 2021.12.1 ~ 2023.11.30 ´ëÇѰ£ÇÐȸ ÀÌ»çÀå
  • 2022.7.29 ~ 2023.9.232023 ¾Æ½Ã¾ÆÅÂÆò¾ç °£ÇÐȸ(APASL) Single Topic Conference Á¶Á÷À§¿øÈ¸ À§¿øÀå
  • 2020.8.25 ~ 2022.4.3 2022 ¾Æ½Ã¾ÆÅÂÆò¾ç °£ÇÐȸ(APASL) Á¶Á÷À§¿øÈ¸ »ç¹«ÃÑÀå
  • 2019.11.1 ~ 2022.10.31´ëÇѳ»°úÇÐȸ ºÐ°ú°ü¸® À§¿øÀå
  • 2017.12.1 ~ 2019.11.30´ëÇѰ£ÇÐȸ Ãѹ«ÀÌ»ç
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis.
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Frontiers in Immunology
Á¦ ¸ñ The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study.
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Clinical and Molecular Hepatology
Á¦ ¸ñ Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups.
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Gut & Liver
Á¦ ¸ñ The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease.
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Diagnostics (Basel)
Á¦ ¸ñ Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation
¹ßÇ¥³âµµ 2024 ¹ßÇ¥Áö Hepatology International
Á¦ ¸ñ Extracellular Superoxide Dismutase Attenuates Hepatic Oxidative Stress in Nonalcoholic Fatty Liver Disease through the Adenosine Monophosphate-Activated Protein Kinase Activation
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Antioxidants(Basel).
Á¦ ¸ñ Intrahepatic infiltration of activated CD8+ T cells and mononuclear phagocyte is associated with idiosyncratic drug-induced liver injury
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Frontiers in Immunology

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

<¸»±â ÁøÇ༺ °£¼¼Æ÷¾Ï Ä¡·á ºÐ¾ß>
°£¼¼Æ÷¾Ï Ä¡·á·Î ¸ÞÆ®·Î³ë¹Í Ä¡·á¹ý(±âÁ¸ÀÇ ÀÏȸ¼º Ä¡·áÀÎ »öÀü¼ú, ÀýÁ¦¼ú·Î´Â Ä¡·á°¡ ¾î·Á¿î ¸»±â °£¾ÏÀ» ¸ÞÆ®·Î³ð°£¼¼Æ÷¾ÏÀÇ Æ¯¼º¿¡ ¸Â°Ô, °£µ¿¸Æ¿¡ Ç×¾ÏÁ¦ ÁÖÀÔÀ» 3Àϰ£ Àå½Ã°£¿¡ °ÉÃÄ ¶ÈµüÀÌ ¹æ½ÄÀ¸·Î ÁÖÀÔ)À¸·Î Ä¡·áÇÑ ¿¬±¸¸¦ ±¹Á¦ ÇмúÁö¿¡ 10Æí ÀÌ»ó ¹ßÇ¥ÇÑ ¾÷Àû

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

¿ÀÄɽºÆ®¶óÀÇ Àü ±¸¼º¿øÀÌ ¾Æ¸§´Ù¿î È­À½À» À§ÇØ ÃÖ¼±À» ´ÙÇØ ¿¬ÁÖÇϵí, º¹ÀâÇÏ°í ¾î·Á¿î °£¾Ï Ä¡·á¸¦ À§ÇØ ¿©·¯ ÀÓ»ó°ú Àü¹® ±³¼öµéÀÌ °¢ÀÚÀÇ Ä¡·á¹ýÀ» ´ÙÇÐÁ¦ ȸÀǸ¦ ÅëÇØ Á¶À²ÇÏ°í ¸ÂÃãÇü Á¢±ÙÀ» ÅëÇØ ¿ì¼±ÀûÀ¸·Î ȯÀÚ°¡ °¡Àå Æí¾ÈÇÏ°Ô Ä¡·á¹ÞÀ» ¼ö ÀÖµµ·Ï Çϸç, ÃÖ°íÀÇ Ä¡·á °á°ú¸¦ ¾òµµ·Ï ÇÒ¶§°¡ °¡Àå ÇູÇÕ´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

°£¾ÏÀ» Áø´Ü¹Þ°Å³ª, °£°æÈ­¸¦ Áø´Ü ¹Þ´õ¶óµµ Á¶±â Áø´ÜÇÏ¸é ¿ÏÄ¡µÉ ¼ö ÀÖ°í, ½ÉÇÏ°Ô ÁøÇàµÇ¾îµµ ÁÁÀº Ä¡·áÁ¦°¡ ÀÖÀ¸´Ï, Àý´ë Æ÷±âÇÏÁö ¸»°í ÀÇ»ç¿Í »óÀÇÇØ¼­ ȯÀںп¡°Ô ¸Â´Â Ä¡·á¸¦ ²À ¹ÞÀ¸½Ã±æ ±ÇÇØµå¸³´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1811-7755
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿øÀº 80¿© ³âÀÇ °¡Å縯 ÀÇ·á ¿ª·®À» ¹ÙÅÁÀ¸·Î, ÃÖ÷´Ü Àåºñ, ¾ÈÀüȯ ȯ°æ, ¿ì¼öÇÑ Áø·á ½Ã½ºÅÛÀ» °®Ãß°í ÀÖ½À´Ï´Ù. À̽Ä, ½ÉÀå, ¾Ï µî ÁßÁõ Áúȯ °í°´µé¿¡°Ô ¿ì¼öÇÑ ÀÇ·áÁøÀÌ ¼öÁØ ³ôÀº Ä¡·á¸¦ Á¦°øÇϸç, ÀÀ±ÞÀÇ·á¼¾ÅÍ¿Í ¼Ò¾ÆÀÀ±Þ½ÇÀ» ¿î¿µÇÏ¿© Áö¿ª»çȸÀÇ ÀÀ±Þ ȯÀڵ鿡°Ô ÇʼöÀûÀÎ ÀÇ·á ¼­ºñ½º¸¦ Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ, °¡Å縯 ÀÇ·á±â°üÀ¸·Î ÀÇ·á Ãë¾à°èÃþÀ» Áö¿øÇÏ´Â µîÀÇ »çȸ°øÇå Ȱµ¿À» Áö¼ÓÀûÀ¸·Î Àü°³Çϰí ÀÖ½À´Ï´Ù.

°¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø 		 À̹ÌÁö

¼­¿ïƯº°½Ã ÀºÆò±¸ ÅëÀÏ·Î 1021

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä